Subtopic Deep Dive

FoxO Phosphorylation by AKT
Research Guide

What is FoxO Phosphorylation by AKT?

FoxO phosphorylation by AKT is the process where AKT kinase phosphorylates FoxO transcription factors in response to insulin and growth factor signaling, causing their nuclear exclusion, cytoplasmic sequestration, and transcriptional inactivation.

This mechanism is central to insulin signaling pathways, with AKT targeting specific threonine and serine residues on FoxO proteins (van der Heide et al., 2004; 691 citations). Phosphorylation disrupts FoxO DNA binding and promotes 14-3-3 protein binding for cytoplasmic retention (Burgering and Kops, 2002; 645 citations). Over 10 key papers from 2002-2013 detail these interactions, with Zhang et al. (2011; 1085 citations) reviewing AKT-FoxO roles in apoptosis regulation.

Curated Papers

Key Challenges

Why It Matters

AKT-FoxO phosphorylation dysregulation contributes to insulin resistance in metabolic syndrome, as shown in mouse models (Guo, 2013; 608 citations). In cancer, hyperactive AKT suppresses FoxO pro-apoptotic functions, promoting cell survival (Zhang et al., 2011; 1085 citations). Therapeutic targeting of this axis holds promise for diabetes and aging interventions, with SIRT3 counteracting FoxO3a inactivation in cardiac protection (Sundaresan et al., 2009; 982 citations).

Key Research Challenges

Structural Mapping of Phosphorylation Sites

Precise AKT-FoxO docking and residue-specific phosphorylation remain incompletely structurally resolved. van der Heide et al. (2004; 691 citations) describe translocation mechanisms but lack atomic-level details. Experimental validation across FoxO isoforms (FoxO1,3,4) is needed for inhibitor design.

Context-Dependent Signaling Crosstalk

AKT-FoxO interacts with oxidative stress (Ral/JNK) and SIRT3 pathways, complicating isolated study. Essers et al. (2004; 780 citations) show JNK activation overrides AKT effects. Integrating multi-omics data poses analytical hurdles (Sundaresan et al., 2009; 982 citations).

Translational Dysregulation in Disease

Hyperinsulinemia-driven AKT hyperactivation in diabetes inactivates FoxO, but therapeutic reversal risks oncogenesis. Guo (2013; 608 citations) highlights metabolic syndrome models. Balancing FoxO reactivation without tumor promotion challenges clinical translation.

Essential Papers

Akt, FoxO and regulation of apoptosis

Xinbo Zhang, Naimei Tang, Timothy Hadden et al. · 2011 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 1.1K citations

Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice

Nagalingam R. Sundaresan, Madhu Gupta, Gene Kim et al. · 2009 · Journal of Clinical Investigation · 982 citations

Sirtuin 3 (SIRT3) is a member of the sirtuin family of proteins that promote longevity in many organisms. Increased expression of SIRT3 has been linked to an extended life span in humans. Here, we ...

FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK

Marieke Essers, Sanne Weijzen, Alida M.M. de Vries-Smits et al. · 2004 · The EMBO Journal · 780 citations

The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation

Lars P. van der Heide, Marco F.M. Hoekman, Marten P. Smidt · 2004 · Biochemical Journal · 691 citations

FoxO (forkhead box O; forkhead members of the O class) are transcription factors that function under the control of insulin/insulin-like signalling. FoxO factors have been associated with a multitu...

Cell cycle and death control: long live Forkheads

Boudewijn Burgering, Geert J.P.L. Kops · 2002 · Trends in Biochemical Sciences · 645 citations

Control of cell number by <i>Drosophila</i> FOXO: downstream and feedback regulation of the insulin receptor pathway

Óscar Puig, Michael T. Marr, Marie-Laure Ruhf et al. · 2003 · Genes & Development · 624 citations

The Drosophila insulin receptor (dInR) regulates cell growth and proliferation through the dPI3K/dAkt pathway, which is conserved in metazoan organisms. Here we report the identification and functi...

The Drosophila Forkhead transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling

Martin A. Jünger, Felix Rintelen, Hugo Stocker et al. · 2003 · Journal of Biology · 611 citations

Reading Guide

Foundational Papers

Start with Burgering and Kops (2002; 645 citations) for core AKT-FoxO inactivation model, then van der Heide et al. (2004; 691 citations) for shuttling details, and Zhang et al. (2011; 1085 citations) for apoptosis integration.

Recent Advances

Prioritize Guo (2013; 608 citations) for disease models and Sundaresan et al. (2009; 982 citations) for SIRT3 modulation of FoxO3a.

Core Methods

Key techniques: site-directed mutagenesis of phospho-sites, GST-14-3-3 pulldowns, Drosophila InR RNAi for in vivo validation (Puig et al., 2003), and microarray for FoxO targets (Wang et al., 2005).

How PapersFlow Helps You Research FoxO Phosphorylation by AKT

Discover & Search

Research Agent uses searchPapers('FoxO AKT phosphorylation sites') to retrieve Zhang et al. (2011; 1085 citations), then citationGraph reveals upstream insulin pathway papers like Guo (2013). exaSearch uncovers niche Drosophila models (Puig et al., 2003), while findSimilarPapers expands to SIRT3 interactions (Sundaresan et al., 2009).

Analyze & Verify

Analysis Agent applies readPaperContent on van der Heide et al. (2004) to extract shuttling motifs, verifies claims via verifyResponse (CoVe) against Essers et al. (2004), and runs PythonAnalysis for citation network stats with pandas on 10 core papers. GRADE grading scores evidence strength for apoptosis claims in Zhang et al. (2011).

Synthesize & Write

Synthesis Agent detects gaps in isoform-specific phosphorylation via contradiction flagging across Burgering papers, generates exportMermaid diagrams of AKT-FoxO-14-3-3 cascades. Writing Agent uses latexEditText for figure legends, latexSyncCitations to integrate 1085-cited Zhang review, and latexCompile for publication-ready reviews.

Use Cases

"Extract and plot FoxO phosphorylation residue frequencies from top 10 AKT papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas frequency table, matplotlib bar plot of Thr/Ser sites from van der Heide 2004 abstracts) → researcher gets CSV-exported residue heatmap.

"Draft LaTeX review section on AKT-FoxO in insulin resistance with citations"

Synthesis Agent → gap detection → Writing Agent → latexEditText (structure section) → latexSyncCitations (add Guo 2013, Zhang 2011) → latexCompile → researcher gets PDF with formatted diagram and bibliography.

"Find GitHub repos analyzing FoxO-AKT signaling simulation models"

Research Agent → paperExtractUrls (from Puig 2003 Drosophila paper) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets runnable SBML models of insulin pathway with FoxO nodes.

Automated Workflows

Deep Research workflow scans 50+ OpenAlex papers on 'FoxO AKT phosphorylation diabetes', chains citationGraph → readPaperContent → GRADE scoring, outputs structured report ranking Guo (2013) highest for translational impact. DeepScan's 7-step analysis verifies AKT dominance over JNK in insulin contexts using CoVe on Essers (2004). Theorizer generates hypotheses on SIRT3-AKT-FoxO3a circuits from Sundaresan (2009) data.

Try Doxa for FoxO Phosphorylation by AKT Research

Frequently Asked Questions

What is FoxO phosphorylation by AKT?

AKT phosphorylates FoxO at Thr24, Ser256, Ser319 residues, promoting 14-3-3 binding and nuclear exclusion (van der Heide et al., 2004; 691 citations).

What are key methods to study AKT-FoxO interactions?

Methods include phosphosite mutagenesis, 14-3-3 co-IP, and Drosophila insulin receptor knockdowns (Puig et al., 2003; 624 citations; Jünger et al., 2003; 611 citations).

What are the most cited papers on this topic?

Top papers: Zhang et al. (2011; 1085 citations) on apoptosis; Sundaresan et al. (2009; 982 citations) on SIRT3-FoxO3a; Essers et al. (2004; 780 citations) on oxidative stress override.

What open problems exist in FoxO-AKT research?

Challenges include isoform-specific inhibitor design, tissue-context crosstalk with SIRT3/JNK, and safe FoxO reactivation in metabolic disease without cancer risk (Guo, 2013; Burgering and Kops, 2002).